ASC47 is an adipose-targeted, once-monthly subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small ...

Ascletis Pharma, Inc. ( ($HK:1672) ) just unveiled an update. Ascletis Pharma Inc. announced promising preclinical results for its ...

U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants with obesity ...

Utilizing this innovative platform, Ascletis has successfully designed and developed two small molecule SQ compounds for obesity with half-lives of 36 days (ASC30) and 40 days (ASC47) in participants ...

Utilizing this innovative platform, Ascletis has successfully designed and developed two small molecule SQ compounds for obesity with half-lives of 36 days (ASC30) and 40 days (ASC47) in ...

The proprietary SQ depot slow-release formulation of ASC30 was developed by Ascletis' Ultra-Long-Acting Platform (ULAP). Utilizing this innovative platform, Ascletis has successfully designed and ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in its U.S. 12 ...

Utilizing this innovative platform, Ascletis has successfully designed and developed two small molecule SQ compounds for obesity with half-lives of 36 days (ASC30) and 40 days (ASC47) in participants ...